Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | GPX4 | P36969 | 1/20 | 0.32 |
| ▸ | CTH | P32929 | 1/20 | 0.32 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20982777 | 0.98 | KDM1A (0.43) | KDM1ALIPGRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL79182 | 0.83 | — | — | |
| SCHEMBL11260 | 0.82 | KDM1A (0.41) | KDM1ALIPGRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL31120943 | 0.80 | MEN1 (0.43) | KDM1ALIPGRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL18519508 | 0.77 | — | — | |
| SCHEMBL12472218 | 0.77 | MCL1 (0.40) | LIPGCYP2D6CYP2C19 | |
| SCHEMBL29957485 | 0.76 | KDM1A (0.39) | KDM1ARAB9ASMN1; SMN2NPC1CYP2D6 | |
| SCHEMBL256677 | 0.73 | — | — | |
| SCHEMBL13844956 | 0.73 | — | — | |
| SCHEMBL21012046 | 0.73 | MCL1 (0.44) | RAB9ASMN1; SMN2NPC1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046716-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200055877-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-20 | — | — | US | disclosed |
| US-10399996-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3347008-A1 | BETA-LACTAMASE INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2018-07-18 | — | — | EP | disclosed |
| US-9902986-B2 | Enterobactin conjugates and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-02-27 | — | — | US | disclosed |
| EP-3218369-A1 | DIARYL ISOXAZOLINE COMPOUND | Novartis Tiergesundheit AG (CH) | 2017-09-20 | — | — | EP | disclosed |
| US-20170073360-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-16 | — | — | US | disclosed |
| WO-2017044828-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2016077158-A1 | DIARYL ISOXAZOLINE COMPOUND | NOVARTIS TIERGESUNDHEIT AG (CH) | 2016-05-19 | — | — | WO | disclosed |
| WO-2015057958-A2 | ENTEROBACTIN CONJUGATES AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20150105337-A1 | ENTEROBACTIN CONJUGATES AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399996-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | KDM1A 447/4885LIPG 146/4885RAB9A 1933/4885 |
| US-20150105337-A1 | ENTEROBACTIN CONJUGATES AND USES THEREOF | BTD, VIP, SLC10A2 | KDM1A 4217/4885LIPG 4064/4885RAB9A 1539/4885 |
| US-20170073360-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | KDM1A 447/4885LIPG 146/4885RAB9A 1933/4885 |
| US-20200055877-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | KDM1A 447/4885LIPG 146/4885RAB9A 1933/4885 |
| US-11046716-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | KDM1A 447/4885LIPG 146/4885RAB9A 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.